CN106834437A - A kind of fragile X mental retardation quick detection kit - Google Patents

A kind of fragile X mental retardation quick detection kit Download PDF

Info

Publication number
CN106834437A
CN106834437A CN201611214263.8A CN201611214263A CN106834437A CN 106834437 A CN106834437 A CN 106834437A CN 201611214263 A CN201611214263 A CN 201611214263A CN 106834437 A CN106834437 A CN 106834437A
Authority
CN
China
Prior art keywords
fragile
detection kit
quick detection
mental retardation
amplified production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201611214263.8A
Other languages
Chinese (zh)
Inventor
刘淑园
陈华云
肖湘文
丁渭
张天海
刘孝礼
邓利琼
陆同山
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GUANGZHOU HESHI BIOTECHNOLOGY Co Ltd
Original Assignee
GUANGZHOU HESHI BIOTECHNOLOGY Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GUANGZHOU HESHI BIOTECHNOLOGY Co Ltd filed Critical GUANGZHOU HESHI BIOTECHNOLOGY Co Ltd
Priority to CN201611214263.8A priority Critical patent/CN106834437A/en
Publication of CN106834437A publication Critical patent/CN106834437A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844Nucleic acid amplification reactions
    • C12Q1/686Polymerase chain reaction [PCR]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention discloses a kind of fragile X mental retardation quick detection kit.A kind of fragile X mental retardation quick detection kit, including:1)The design gene 5' ends non-translational regions of FMR 1(CGG duplicate blocks)Sense primer and anti-sense primer;2)Upstream and downstream primer and high-fidelity enzyme, 10 × PCR buffer etc. mix, and enter performing PCR amplification;3)Amplified production is carried out into agarose electrophoresis, the substantially copy number of CGG is judged by judging the clip size of amplified production, so as to judge whether tester is fragile X syndrome patient or carrier.The amplified production fragment of normal person<300bp, if in the presence of>The amplified production of 700bp, then be premutation person or full mutation person.The design of primers difficulty used in detection method of the invention is low, significantly reduces the cost of primer synthesis;The agarose electrophoresis method judged result of use, further reduces testing cost, substantially increases Clinical practicability.

Description

A kind of fragile X mental retardation quick detection kit
Technical field
The present invention relates to biological technical field, more particularly to a kind of fragile X mental retardation quick detection kit.
Background technology
Fragile X syndrome causes patient's amentia(Martin-Bell syndromes), it is that a kind of clinical manifestation is mainly The x linked recessive genetic disease of feeblemindedness, most of mechanism of causing a disease is FMR-1 gene 5' ends non-translational region(CGG)n Three nucleic acids repeat sequence transmission extremely and cause.Normal person's(CGG)Repeat copy number and be about 30 copies(90bp), and women The copy number that repeats of carrier and normal male transmitter increases to 150 ~ 500bp, is referred to as premutation, and adjacent CpG islands are not It is methylated, this premutation(premutation)Nothing or only light symptoms.Full mutation is converted into by premutation mother only occurs Parent is in offspring's transmittance process:The CGG areas of female carrier are unstable, can cause fragile site high in offspring's transmittance process The female carrier and male patient of expression increase to 1000 ~ 3000bp, and adjacent CpG islands are also methylated, this full mutation The expression of neighboring gene can be closed, so as to clinical symptoms occur.
The incidence of disease of fragile X syndrome is about 1/1200 ~ 1/2500 in males, in women population About 1/2000.And the performance of the complicated clinical manifestation of fragile X syndrome, particularly female carrier is not obvious, hold Easily increase newborn infant.Presently mainly by genetic counselling and the reduction of pre-natal diagnosis means, the birth of the newborn infant of prevention, from And reduce the incidence of disease of fragile X mental retardation.
To reduce the incidence of disease of fragile X mental retardation, according to the understanding to fragile site DNA sequence dna, can be connected with RFLP The methods such as lock analysis, DNA hybridization analysis, real-time fluorescence quantitative PCR amplification detect Disease-causing gene, but all because costly, or Time-consuming etc. that reason limits its application for person.A kind of fragile X mental retardation quick detection kit of the invention avoids prior art Shortcoming, it can be by detecting the copy number of the CGG of FMR-1 genes, so as to quickly, accurately judge whether tester is fragility X chromosome syndrome patient or carrier, reduce Newborn Birth-defects rate, are that the prenatal and postnatal care engineering in the whole nation contributes.
The content of the invention
It is an object of the invention to provide a kind of fragile X mental retardation quick detection kit.
The technical solution used in the present invention is:
1) design is directed to FMR-1 gene 5' ends non-translational region(CGG duplicate blocks)Sense primer and anti-sense primer.
2) upstream and downstream primer and high-fidelity enzyme, 10 × PCR buffer etc. are mixed, is expanded.
3) amplified production is carried out into agarose electrophoresis, CGG is judged substantially by judging the clip size of amplified production Copy number, so as to judge whether tester is fragile X syndrome patient or carrier.The amplified production fragment of normal person <300bp, if in the presence of>The amplified production of 700bp, then be premutation person or full mutation person.
As the further improvement of the above method, PCR synergist is with the addition of in PCR system, promote primer-masterplate annealing And aid in archaeal dna polymerase to extend through secondary structure area.
Particularly, a kind of sequence of the primer of above-mentioned fragile X mental retardation quick detection kit is as follows:
F:5'-GCTCAGCTCCGTTTCGGTT-3'
R:5'-ATTGGAGCCCCGCACTTC-3'
Brief description of the drawings
Fig. 1 is the agarose electrophoresis figure of the DNA cloning product of normal person and fragile X mental retardation patient.Distinguish from left to right It is passage 1 ~ 7.Passage 1~3 is the DNA cloning product of fragile X syndrome patient;Passage 4~6 is normal person's DNA cloning product; Passage 7 is 100bp Marker.
Specific embodiment
Embodiment 1:A kind of compound method of fragile X mental retardation quick detection kit
1st, primer:Repeat to go to design primer, including sense primer F and anti-sense primer R in the CGG of FRM-1 genes.
2、10×PCR buffer:Its component mainly includes the Tris-AC of 50mM(pH9.2), the KAC of 50mM, 20mM's (NH4)2SO4, the MgCl of 10mM2
Embodiment 2:Using QIAamp DNA Blood Mini Kit (the 50)-reagent of article No. 51104 of QIAGEN companies Box carries out nucleic acid extraction, obtains sample to be checked.
Embodiment 3:Detection sample
Use the PCR amplification system of embodiment 1:
Tris-AC(pH9.2) 50mM
KAC 50mM
20mM
10mM
dNTPs 300μM
High-fidelity enzyme 4U
DMSO 6%
Glycine betaine 5M
F 10pmol
R 10pmol
DNA 50ng
Its PCR amplification condition:
After reaction terminates, PCR primer is carried out into agarose electrophoresis, it can be seen that normal person exists<There is clear band at 300bp(Figure 1), and fragile X mental retardation patient exists>There is clear band at 700bp(Fig. 1).This result illustrates that this kit can be with quick detection Fragile X mental retardation.
SEQUENCE LISTING
<110>Guangzhou two kinds of substance synthesis into another Technology Co., Ltd.
<120>A kind of fragile X mental retardation quick detection kit
<130> 2016
<160> 2
<170> PatentIn version 3.5
<210> 1
<211> 19
<212> DNA
<213>Artificial sequence
<400> 1
gctcagctcc gtttcggtt 19
<210> 2
<211> 18
<212> DNA
<213>Artificial sequence
<400> 2
attggagccc cgcacttc 18

Claims (5)

1. a kind of fragile X syndrome quick detection kit, including:Expand the sense primer F of the CGG duplicate blocks of FMR-1 genes With anti-sense primer R;High-fidelity enzyme;10 × PCR buffer etc..
2. it is respectively according to the sense primer F and anti-sense primer R described in claim 1:
F:5'-GCTCAGCTCCGTTTCGGTT-3'
R:5'-ATTGGAGCCCCGCACTTC-3'。
3. PCR amplification system according to claim 1 is:
4. a kind of PCR amplification conditions of fragile X syndrome quick detection kit according to claim 1 are:
5. a kind of judged result method of fragile X syndrome quick detection kit according to claim 1 is agarose Electrophoresis.
CN201611214263.8A 2016-12-26 2016-12-26 A kind of fragile X mental retardation quick detection kit Withdrawn CN106834437A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201611214263.8A CN106834437A (en) 2016-12-26 2016-12-26 A kind of fragile X mental retardation quick detection kit

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201611214263.8A CN106834437A (en) 2016-12-26 2016-12-26 A kind of fragile X mental retardation quick detection kit

Publications (1)

Publication Number Publication Date
CN106834437A true CN106834437A (en) 2017-06-13

Family

ID=59136307

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201611214263.8A Withdrawn CN106834437A (en) 2016-12-26 2016-12-26 A kind of fragile X mental retardation quick detection kit

Country Status (1)

Country Link
CN (1) CN106834437A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108866176A (en) * 2017-07-11 2018-11-23 北京阅微基因技术有限公司 The detection architecture and detection kit of a kind of pair of FMR1 gene 5 ' non-translational region CGG unit number of iterations

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101871001A (en) * 2009-04-22 2010-10-27 中山大学达安基因股份有限公司 Kit for detecting fragile X syndrome
CN102242187A (en) * 2010-05-11 2011-11-16 北京康为世纪生物科技有限公司 PCR (polymerase chain reaction) detection method for CGG repeat number of FMR1 (fragile X mental retardation 1) gene 5' terminal noncoding region
WO2014015273A1 (en) * 2012-07-20 2014-01-23 Asuragen, Inc. Comprehensive fmr1 genotyping
CN103981254A (en) * 2014-03-27 2014-08-13 江苏佰龄全基因生物医学技术有限公司 Clinic rapid PCR detection kit of fragile X syndrome

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101871001A (en) * 2009-04-22 2010-10-27 中山大学达安基因股份有限公司 Kit for detecting fragile X syndrome
CN102242187A (en) * 2010-05-11 2011-11-16 北京康为世纪生物科技有限公司 PCR (polymerase chain reaction) detection method for CGG repeat number of FMR1 (fragile X mental retardation 1) gene 5' terminal noncoding region
WO2014015273A1 (en) * 2012-07-20 2014-01-23 Asuragen, Inc. Comprehensive fmr1 genotyping
CN103981254A (en) * 2014-03-27 2014-08-13 江苏佰龄全基因生物医学技术有限公司 Clinic rapid PCR detection kit of fragile X syndrome

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
王旻等: "《生物工程》", 30 August 2015, 北京:中国医药科技出版社 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108866176A (en) * 2017-07-11 2018-11-23 北京阅微基因技术有限公司 The detection architecture and detection kit of a kind of pair of FMR1 gene 5 ' non-translational region CGG unit number of iterations
CN108866176B (en) * 2017-07-11 2021-09-14 北京阅微基因技术股份有限公司 Detection system and detection kit for repeated number of CGG units in 5' untranslated region of FMR1 gene

Similar Documents

Publication Publication Date Title
JP6871160B2 (en) Methods for Identifying and Quantifying Nucleic Acid Expression, Splice Variants, Translocations, Copy Counts, or Methylation Changes
JP5789605B2 (en) Chromosome aneuploidy detection method
US9719140B2 (en) Direct molecular diagnosis of fetal aneuploidy
JP6739339B2 (en) Covered sequence-converted DNA and detection method
JP6496665B2 (en) Methods and primer sets for high-throughput PCR sequencing
CN102533985B (en) Method for detecting deletion and/or duplication of exons in DMD gene
CN102808026B (en) Primer, probe, fluorescent PCR kit and method for detecting polymorphism of human MTHFR (Methylene Tetrahydrofolate Reductase) gene
CN101611155B (en) Diagnostic sequences for shrimp pathogens
CN111183229A (en) Digital amplification using primers with limited nucleotide composition
CN115335536B (en) Compositions and methods for on-the-fly nucleic acid detection
WO2013116039A1 (en) Amplification primers and probes for detection of hiv-1
WO2021177372A1 (en) METHOD FOR DETECTING CORONAVIRUS (SARS-CoV-2)
US8153401B2 (en) Method for direct amplification from crude nucleic acid samples
CN107083427B (en) DNA ligase mediated DNA amplification technology
CN106834437A (en) A kind of fragile X mental retardation quick detection kit
CN106868218B (en) Multiple PCR kit for rapid diagnosis of viral encephalitis
JP5258760B2 (en) Method for amplifying methylated or unmethylated nucleic acid
WO2007105673A1 (en) Method for detection of mutant gene
CN108300776A (en) Fragile X mental retardation fast screening reagent kit
US20240167107A1 (en) Composition and method for nucleic acid detection
KR101912488B1 (en) Molecular detection assay
WO2012083845A1 (en) Methods for removal of vector fragments in sequencing library and uses thereof
JPWO2006070666A1 (en) Simultaneous detection method of gene polymorphism
WO2018232597A1 (en) Composition used for quantitative pcr amplification and application thereof
JP6976567B2 (en) Sample preparation method for DNA methylation analysis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication

Application publication date: 20170613

WW01 Invention patent application withdrawn after publication